What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid…
What is Enliven Therapeutics, Inc.'s P/E and P/B ratio?
Enliven Therapeutics, Inc. has a P/E ratio of -25.1 and a P/B ratio of 3.43.
What is Enliven Therapeutics, Inc.'s debt-to-equity ratio?
Enliven Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Enliven Therapeutics, Inc. owe compared with what it owns?
Enliven Therapeutics, Inc. owes $0.02 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Enliven Therapeutics, Inc.'s Positivity rank?
Enliven Therapeutics, Inc. is ranked #4,695 of 6,775 companies globally and #2,405 of 4,000 in United States on PositoAI, with a Positivity Score of 19,142.
Does Enliven Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Enliven Therapeutics, Inc..
Where can I read the latest news about Enliven Therapeutics, Inc.?
Recent headlines about Enliven Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Enliven Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Enliven Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.